87 194

Cited 5 times in

Prognostic Scoring Index for Patients with Metastatic Pancreatic Adenocarcinoma.

 Hyung Soon Park  ;  Hye Sun Lee  ;  Ji Soo Park  ;  Joon Seong Park  ;  Dong Ki Lee  ;  Se-Joon Lee  ;  Dong Sup Yoon  ;  Min Goo Lee  ;  Hei-Cheul Jeung 
 Cancer Research and Treatment, Vol.48(4) : 1253-1263, 2016 
Journal Title
 Cancer Research and Treatment 
Issue Date
Adenocarcinoma/blood ; Adenocarcinoma/diagnostic imaging ; Adenocarcinoma/pathology* ; Adult ; Aged ; Aged, 80 and over ; Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/pathology* ; Brain Neoplasms/secondary ; Carcinoembryonic Antigen/blood ; Female ; Humans ; Leukocyte Count ; Lymphocytes/pathology ; Male ; Middle Aged ; Neoplasm Metastasis ; Neutrophils/pathology ; Pancreatic Neoplasms/blood ; Pancreatic Neoplasms/diagnostic imaging ; Pancreatic Neoplasms/pathology* ; Prognosis* ; Proportional Hazards Models ; Risk Factors ; Severity of Illness Index*
Pancreatic neoplasms ; Prognosis ; Research design ; Survival
PURPOSE: This study focused on implementation of a prognostic scoring index based on clinico-laboratory parameters measured routinely on admission in metastatic pancreatic cancer patients. MATERIALS AND METHODS: Records from 403 patients of metastatic disease were analyzed retrospectively. Continuous variables were dichotomized according to the normal range or the best cut-off values statistically determined by Contal and O'Quigley method, and then analyzed in association with prognosis-overall survival (OS), using Cox's proportional hazard model. Scores were calculated by summing the rounded chi-square scores for the factors that emerged in the multivariate analysis. RESULTS: Performance status, hemoglobin, leucocyte count, neutrophil-lymphocyte ratio, and carcinoembryonic antigen were independent factors for OS. When patients were divided into three risk groups according to these factors, median survival was 11.7, 6.2, and 1.3 months for the low, intermediate, and high-risk groups, respectively (p < 0.001). Palliative chemotherapy has a significant survival benefit for low and intermediate-risk patients (median OS; 12.5 months vs. 5.9 months, p < 0.001 and 8.0 months vs. 2.0 months, p < 0.001, respectively). CONCLUSION: We advocate the use of a multivariable approach with continuous variables for prognostic modeling. Our index is helpful in accurate patient risk stratification and may aid in treatment selection.
Files in This Item:
T201604234.pdf Download
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pharmacology (약리학교실)
Yonsei Authors
박준성(Park, Joon Seong) ORCID logo https://orcid.org/0000-0001-8048-9990
박지수(Park, Ji Soo) ORCID logo https://orcid.org/0000-0002-0023-7740
박형순(Park, Hyung Soon)
윤동섭(Yoon, Dong Sup)
이동기(Lee, Dong Ki) ORCID logo https://orcid.org/0000-0002-0048-9112
이민구(Lee, Min Goo) ORCID logo https://orcid.org/0000-0001-7436-012X
이세준(Lee, Se Joon)
정희철(Jeung, Hei Cheul)
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.